Is MDGL a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Madrigal Pharmaceuticals (MDGL) rests on Rezdiffra revenue ramp: Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, crossing $1.1 billion on a trailing-twelve-month basis less than two years after launch. Revenue (TTM) is ~$1.1B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Whether MDGL is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a commercial-stage biopharmaceutical company built around Rezdiffra (resmetirom), an oral thyroid hormone receptor beta agonist that in March 2024 became the first FDA-approved treatment for MASH with moderate to advanced fibrosis. The company has transitioned from a clinical-stage developer into a revenue-generating commercial operation, with more than 42,250 patients on Rezdiffra as of the first quarter of 2026 and a US sales force focused on liver specialists and the roughly 460,000 diagnosed F2/F3 MASH patients being seen by those doctors. The investment picture is a concentrated bet on a single blockbuster-track drug. Rezdiffra revenue grew 127% year over year to about $311 million in the first quarter of 2026 and has surpassed $1.1 billion on a trailing basis, yet Madrigal still runs at a net loss as it invests heavily in commercial reach, label expansion and pipeline. The stock trades on the durability of that revenue ramp and on how well the company defends its first-mover position as GLP-1 drugs and FGF21 analogs move into the MASH market.
What's the case for buying MDGL?
1. Rezdiffra revenue ramp
Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, crossing $1.1 billion on a trailing-twelve-month basis less than two years after launch. Patient count reached more than 42,250, up about 2.5x from a year earlier. The central driver is whether that adoption curve keeps compounding as more prescribers and diagnosed patients enter the funnel.
2. MASH market expansion
The diagnosed F2/F3 MASH population seen by target liver specialists in the US grew nearly 50% from about 315,000 to 460,000 patients between year-end 2023 and year-end 2025. A larger diagnosed pool and rising disease awareness expand the addressable market Rezdiffra can penetrate as the first approved therapy.
3. Label and pipeline expansion
Madrigal is pursuing broader use of resmetirom, including in earlier and more advanced (compensated cirrhosis) MASH populations, and has added assets through business development, including an RNAi MASH deal sourced from China. Success in widening the label and building a multi-asset pipeline would reduce reliance on a single indication.
4. Path toward profitability
The company reported a net loss of about $94 million in the first quarter of 2026 against roughly $404 million of operating expenses, ending the period with about $818 million in cash and marketable securities. The bull case rests on revenue scaling past a heavy commercial and R&D cost base to reach sustained profitability.
What are the risks to MDGL?
MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Competition is intensifying: Novo Nordisk's Wegovy won FDA approval in MASH in 2025, and late-stage rivals include Viking Therapeutics' VK2809 and FGF21 analogs such as Akero's efruxifermin, 89Bio's pegozafermin and GSK's efimosfermin. The company remains unprofitable and could need additional capital or carry debt (it has an outstanding term loan) if losses persist. Valuation is rich relative to current sales, leaving little room for execution stumbles. Biotech-specific risks around clinical trials, regulatory decisions and manufacturing also apply.
How is MDGL valued? (as of JULY 2026)
Snapshot for MDGL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.1B
- Q1 2026 Rezdiffra net sales: ~$311M (+127% YoY)
- Q1 2026 net loss: ~$94M
- Market cap: ~$12B
- Price/sales (TTM): ~11x
- Cash and marketable securities: ~$818M
Madrigal is valued as a high-growth commercial biotech, trading around 11 times trailing sales while still reporting quarterly losses as it funds commercialization. The market is pricing in continued rapid revenue growth from Rezdiffra rather than current earnings. Figures are approximate and drawn from first-quarter 2026 reporting.
How do you decide if MDGL is a buy?
Rather than asking whether MDGL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MDGL indirectly through an index or sector ETF before adding more.
For the full picture, see the MDGL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MDGL against your real portfolio and see your actual exposure before deciding.
The bottom line on MDGL
The bottom line: Madrigal Pharmaceuticals's story right now is Rezdiffra revenue ramp, with revenue (ttm) at ~$1.1B. If you believe that narrative continues, the call is about sizing MDGL sensibly and checking overlap with what you own; if you doubt it (the risk: mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on MDGL
- MDGL stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- MDGL stock forecast (the drivers and risks shaping the outlook)
- Does MDGL pay a dividend?
Build a basket around MDGL with Walnut
Use Madrigal Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MDGL a good stock to buy right now?
+
The case for Madrigal Pharmaceuticals right now is Rezdiffra revenue ramp, with revenue (ttm) at ~$1.1B. If you believe that thesis holds, MDGL is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Madrigal Pharmaceuticals do?
+
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a commercial-stage biopharmaceutical company built around Rezdiffra (resmetirom), an oral thyroid hormone receptor beta agonist that in M
What are the main risks of MDGL?
+
MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Competition is intensifying: Novo Nordisk's Wegovy won FDA approval in MASH in 2025, and late-stage rivals include Viking Therapeutics' VK2809 and FGF21 analogs such as Akero's efruxifermin, 89Bio's pegozafermin and GSK's efimosfermin. The company remains unprofitable and could need additional capital or carry debt (it has an outstanding term loan) if losses persist. Valuation is rich relative to current sales, leaving little room for execution stumbles. Biotech-specific risks around clinical trials, regulatory decisions and manufacturing also apply.
What does Madrigal Pharmaceuticals do?
+
Madrigal is a commercial-stage biopharmaceutical company focused on liver and metabolic disease. Its lead product, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and drives essentially all of the company's revenue.
What exchange is MDGL listed on?
+
MDGL trades on the Nasdaq Stock Market under the ticker MDGL. It is a US-based company, so investors can access it through a standard US brokerage account.
What is Rezdiffra?
+
Rezdiffra (resmetirom) is an oral, once-daily thyroid hormone receptor beta agonist. Approved by the FDA in March 2024, it was the first therapy cleared specifically for MASH (formerly called NASH) in adults with moderate to advanced liver fibrosis.
Is Madrigal profitable?
+
No. Despite rapidly growing Rezdiffra sales, Madrigal reported a net loss of roughly $94 million in the first quarter of 2026 as it invests heavily in commercialization and research. The company ended the quarter with about $818 million in cash and marketable securities.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MDGL; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.